Phase 3 Clinical Trials With Primary Completion Dates in October 2026
This is a list of Phase 3 trials with primary completion dates in October 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc. | 2026-10-01 | Phase 3 | NCT06455202 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) |
| CLDX | Celldex Therapeutics, Inc. | 2026-10-01 | Phase 3 | NCT06445023 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria |
| EYPT | EyePoint, Inc. | 2026-10-01 | Phase 3 | NCT06683742 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 |
| LLY | Eli Lilly and Company | 2026-10-01 | Phase 3 | NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
| LLY | Eli Lilly and Company | 2026-10-01 | Phase 3 | NCT06297603 | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) |
| LLY | Eli Lilly and Company | 2026-10-01 | Phase 3 | NCT04088396 | A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) |
| MIRM | Mirum Pharmaceuticals, Inc. | 2026-10-01 | Phase 3 | NCT06553768 | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) |
| OGN | Organon & Co. | 2026-10-01 | Phase 3 | NCT05172726 | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects |
| RGNX | REGENXBIO Inc. | 2026-10-01 | Phase 3 | NCT05407636 | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD |
| XENE | Xenon Pharmaceuticals Inc. | 2026-10-01 | Phase 3 | NCT05716100 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) |